Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: April 1, 2011
Last updated: November 16, 2016
Last verified: November 2016
The purpose of this extension study is to assess the long-term safety and tolerability of omalizumab as an add-on therapy in Japanese pediatric patients (6 to 15 years of age) with inadequately controlled allergic asthma despite current recommended treatment by providing continued treatment with omalizumab to patients who have previously completed the core study.

Condition Intervention Phase
Allergic Asthma
Drug: Omalizumab
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Current Recommended Treatment

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • To assess the long-term safety and tolerability of omalizumab by measuring AEs, serious AEs, physical examination, medical history, laboratory assessments and vital signs [ Time Frame: Every 3 months for approximately 2 years ]

Secondary Outcome Measures:
  • To explore the efficacy of omalizumab by JPAC questionnaire; JPAC is the Japan Pediatric Asthma Control Program (JPAC) [ Time Frame: Every 3 months for approximately 2 years ]
  • To explore the efficacy of omalizumab by QOL questionnaire score (Quality of life questionnaires for pediatric patients with bronchial asthma and their parents or caregivers (Gifu)) [ Time Frame: Every 3 months for approximately 2 years ]
  • To explore the efficacy of omalizumab by use of asthma long-term control medications [ Time Frame: Every 3 months for approximately 2 years ]
  • To explore the efficacy of omalizumab by Pulmonary function (FEV1, FVC, V(・)50, V(・)25 and FEF25-75%) [ Time Frame: Every 3 months for approximately 2 years ]
  • To collect the data on the number of hospitalizations, emergency room (ER) visits due to asthma [ Time Frame: Every 3 months for approximately 2 years ]

Enrollment: 38
Study Start Date: March 2011
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Omalizumab Drug: Omalizumab
omalizumab lyophilized 150 mg injection


Ages Eligible for Study:   6 Years to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who completed the core study (IGE025B1301) and who in the investigator's clinical judgment could benefit from continuous treatment of the study drug.

Exclusion Criteria:

  • Patients who currently have diagnosed cancer, are currently being investigated for possible cancer or have any history of cancer.
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are: women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner; women whose partners have been sterilized by vasectomy or other means; using a highly effective method of birth control; or agreeing on total abstinence and the investigator also judges that the age, career lifestyle or sexual orientation of the patient ensures compliance.
  • With clinically significant uncontrolled systemic disease (eg: infection, hematological disease, renal, hepatic, coronary heart disease or other cardiovascular disease, cerebro-vascular, endocrinologic or gastrointestinal disease) after the treatment period of the core study.
  • Patients with a history of major protocol violations during the core study and who are considered potentially unreliable as judged by the investigator at each site.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01328886

Novartis Investigative Site
Ohbu, Aichi, Japan, 474-0031
Novartis Investigative Site
Sagamihara-city, Kanagawa, Japan, 228-8522
Novartis Investigative Site
Yokohama, Kanagawa, Japan, 232-8555
Novartis Investigative Site
Yokohama, Kanagawa, Japan, 245-8575
Novartis Investigative Site
Tsu, Mie, Japan, 514-0125
Novartis Investigative Site
Tenri, Nara, Japan, 632-8552
Novartis Investigative Site
Habikino city, Osaka, Japan, 583-8588
Novartis Investigative Site
Shimotsuka-gun, Tochigi, Japan, 321-0293
Novartis Investigative Site
Fuchu, Tokyo, Japan, 183-8561
Novartis Investigative Site
Komae, Tokyo, Japan, 201-8601
Novartis Investigative Site
Setagaya-ku, Tokyo, Japan, 158-0097
Novartis Investigative Site
Sumida-ku, Tokyo, Japan, 130-8587
Novartis Investigative Site
Chiba, Japan, 266-0007
Novartis Investigative Site
Fukuoka, Japan, 811-1394
Novartis Investigative Site
Gifu, Japan, 501-1194
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01328886     History of Changes
Other Study ID Numbers: CIGE025B1301E1
Study First Received: April 1, 2011
Last Updated: November 16, 2016

Keywords provided by Novartis:
allergic asthma
pediatric patients

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anti-Allergic Agents
Anti-Asthmatic Agents
Respiratory System Agents processed this record on April 28, 2017